Delivery Order SPE2DB24D6044-SPE2DB25FLJNU
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $96,699.54 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on September 5, 2025, with completion scheduled for September 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,527.14 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 7, 2025, with completion targeted for August 8, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award executed under the company's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be supplied from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a contract ceiling value of $44,612.34. This firm fixed-price delivery order, with an ultimate completion date of September 18, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded a $11,697.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and represents a pediatric or maintenance supply delivery under DLA's medical procurement operations. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $15,385.14 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 29, 2025, with an ultimate completion date of September 2, 2025. This non-competitive, firm fixed-price delivery order will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal...
- The Defense Logistics Agency (DLA) awarded a $109,423.55 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on September 17, 2025, with an ultimate completion date of September 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $54,265.48 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on September 11, 2025, with an ultimate completion date of September 12, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded procurement under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery order will be fulfilled from...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,838.25 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 11, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 12, 2025, represents a non-competitive set-aside award issued under DLA's broader pharmaceutical procurement framework. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a primary pharmaceutical distributor for...
- SPE2DB24D6044Indefinite Delivery Contract
- SPE2DB24D6044-SPE2DB25FLJNUDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp valued at $59,873.00 for the supply of Dupixent 300 mg/2 ml pen injectors on September 26, 2025. This firm fixed price, competitively awarded delivery order is scheduled for completion by September 29, 2025, with fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating open competition among qualified vendors. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion prime contract vehicle designated SPE2DX and running through December 2026. This comprehensive global pharmaceutical support contract enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and vaccines. The current award for Dupixent, a biologic treatment for eczema and asthma, reflects the company's ongoing role as a critical pharmaceutical distributor for federal medical procurement needs serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $59.9k | 9/26/25 |